BioMed Research International / 2023 / Article / Tab 2 / Review Article
A Systematic Review on the Occurrence of Antimicrobial-Resistant Escherichia coli in Poultry and Poultry Environments in Bangladesh between 2010 and 2021 Table 2 Phenotypic antimicrobial resistance profiles of E. coli sourced from poultry in Bangladesh (articles published from 2010 to 2021).
Study ID (no. of isolates tested) Name of antibiotics No. of resistant E. coli (%) 95% CI Penicillins and beta-lactamase inhibitors Parvez et al. [28 ] (11) AMX 11 (100) 74.1-100 Runa et al. [29 ] (5) AMP 5 (100) 56.6-100 P 5 (100) 56.6-100 Khatun et al. [30 ] (42) P 42 (100) 91.6-100 AMX 42 (100) 91.6-100 Al-Salauddin et al. [31 ] (50) AMX 40 (83.3) 71.9-90.7 Sarker et al. [32 ] (37) AMP 37 (100) 90.6-100 Islam et al. [34 ] (17) AMX 15 (88.2) 76.7-97.9 Amin et al. [7 ] (14) AMP 14 (100) 78.5-100 TAZ 4 (28.6) 1.7-54.7 Saha et al. [36 ] (114) AMP 84 (73.7) 64.9-80.9 Al Azad et al. [37 ] (400) AMP 400 (100) 99.1-100 Parvin et al. [40 ] (86) AMP 77 (89.5) 81.3-94.4 AMX 79 (91.9) 84.1-96.0 AMC 36 (41.9) 32.0-52.4 TAZ 61 (70.9) 60.6-79.4 Ievy et al. [41 ] (36) AMP 36 (100) 90.4-100 Rahman et al. [42 ] (381) AMP 377 (98.9) 97.3-99.6 Mandal et al. [43 ] (114) AMC 23 (20.2) 13.9-28.5 Cephalosporins Khatun et al. [30 ] (42) CPX 42 (100) 91.6-100 Sarker et al. [32 ] (37) CRO 5 (13.5) 5.9-27.9 Amin et al. [7 ] (14) CRO 14 (100) 78.5-100 CTX 14 (100) 78.5-100 CAZ 8 (57.1) 32.6-78.6 CFM 13 (92.9) 68.5-99.6 FEP 12 (85.7) 60.1-97.5 Parvin et al. [40 ] (86) CPX 40 (46.5) 36.4-56.9 CE 43 (50) 39.7-60.3 CXM 37 (43) 33.1-53.6 CEC 13 (15.1) 9.1-24.2 CAZ 25 (29.1) 20.5-39.4 CRO 2 (2.3) 0.4-8.1 CTX 46 (53.5) 43.0-63.7 FEP 62 (72.1) 61.8-80.5 Mandal et al. [43 ] (114) CAZ 2 (1.8) 0.3-6.2 CRO 9 (7.9) 4.2-14.3 CTX 89 (78.1) 69.6-84.7 Carbapenems Saha et al. [36 ] (114) IMP 26(22.8) 16.1-31.3 Sobur et al. [38 ] (44) ERT 29 (65.9) 51.1-78.1 MEM 19 (43.2) 29.7-57.8 IMP 6 (13.6) 6.4-26.7 Tawyabur et al. [39 ] (55) MEM 40 (72.7) 59.8-82.7 Parvin et al. [40 ] (86) IMP 41 (47.7) 37.5-58.1 MEM 36 (41.9) 32.0-52.4 Mandal et al. [43 ] (114) IMP 75 (65.8) 56.7-73.9 MEM 58 (50.9) 41.8-59.9 Fluoroquinolones Parvez et al. [28 ] (11) CIP 9 (81.8) 52.3-96.8 LEV 8 (72.7) 43.4-90.3 Khatun et al. [30 ] (42) NA 42 (100) 91.6-100 Al-Salauddin et al. [31 ] (50) CIP 3 (6) 1.6-16.2 NOR 3 (6) 1.6-16.2 Sarker et al. [32 ] (37) CIP 13 (35.1) 21.8-51.2 NA 34 (91.9) 78.7-97.2 Mahmud et al. [33 ] (18) GAT 7 (38.9) 20.3-61.4 LEV 4 (22.2) 9.0-45.2 MOX 10 (55.6) 33.7-75.4 PLX 11 (61.1) 38.6-79.7 OFX 10 (55.6) 33.7-75.4 Islam et al. [34 ] (17) NOR 1 (5.98) 0.3-26.9 Das et al. [35 ] (97) CIP 76 (78.4) 69.2-85.4 Amin et al. [7 ] (14) CIP 12 (85.7) 60.1-97.5 NA 12 (85.7) 60.1-97.5 Saha et al. [36 ] (114) CIP 51 (44.7) 35.9-53.9 NA 87 (76.3) 67.7-83.2 Al Azad et al. [37 ] (400) CIP 400 (100) 99.1-100 LEV 332 (83) 79.0-86.4 Tawyabur et al. [39 ] (55) LEV 15 (27.3) 17.3-40.2 CIP 37 (67.3) 54.1-78.2 Parvin et al. [40 ] (86) CIP 38 (44.2) 34.2-54.7 NA 53 (61.6) 51.1-71.2 LEV 29 (33.7) 24.6-44.2 NOR 37 (43) 33.1-53.7 GAT 43 (50) 39.7-60.3 PLX 76 (88.4) 79.9-93.6 OFX 49 (56.9) 46.4-66.9 Ievy et al. [41 ] (36) EN 20 (55.6) 39.6-70.5 NOR 18 (50) 34.5-65.5 CIP 18 (50) 34.5-65.5 Mandal et al. [42 ] (114) LEV 93 (81.6) 73.5-87.6 CIP 80 (70.2) 61.2-77.8 Aminoglycosides Runa et al. [29 ] (5) NEO 5 (100) 56.6-100 Khatun et al. [30 ] (42) GEN 42 (100) 91.6-100 Al-Salauddin et al. [31 ] (50) GEN 3 (6) 1.6-16.2 S 19 (38) 25.9-51.9 Sarker et al. [32 ] (37) GEN 6 (16.2) 7.7-31.1 Islam et al. [33 ] (17) GEN 2 (11.8) 2.1-34.3 S 3 (17.7) 6.2-41.0 Amin et al. [7 ] (14) GEN 10 (71.4) 45.4-88.3 Saha et al. [36 ] (114) GEN 30 (26.3) 19.1-35.1 Al Azad et al. [37 ] (400) S 400 (100) 99.1-100 GEN 204 (51) 46.1-55.9 Tawyabur et al. [39 ] (55) S 9 (16.4) 8.9-28.3 GEN 9 (16.4) 8.9-28.3 Parvin et al. [40 ] (86) GEN 7 (8.1) 3.9-15.9 TOB 7 (8.1) 3.9-15.9 AMK 15 (17.4) 10.9-26.8 S 50 (58.1) 47.6-67.9 NEO 24 (27.9) 19.5-38.2 Ievy et al. [41 ] (36) S 7 (19.4) 9.8-35.0 GEN 3 (8.3) 2.9-21.8 Rahman et al. [42 ] (381) S 270 (70.9) 66.1-75.2 GEN 105 (27.6) 23.3-32.3 Tetracyclines Parvez et al. [28 ] (11) TE 11 (100) 74.1-100 Al-Salauddin et al. [31 ] (50) TE 11 (22) 12.8-35.2 Sarker et al. [32 ] (37) TE 37 (100) 90.6-100 Islam et al. [34 ] (17) TE 3 (17.7) 6.2-41.0 Das et al. [35 ] (97) OXT 97 (100) 96.2-100 Amin et al. [7 ] (14) TE 14 (100) 78.5-100 Saha et al. [36 ] (114) DOX 90 (78.9) 70.6-85.4 TE 86 (75.4) 66.8-82.4 Al Azad et al. [37 ] (400) TE 400 (100) 99.1-100 Tawyabur et al. [39 ] (55) TE 29 (52.7) 39.8-65.3 Parvin et al. [40 ] (86) TE 73 (84.9) 75.8-90.9 OXT 80 (93) 85.6-96.8 DOX 59 (68.6) 58.2-77.4 Ievy et al. [41 ] (36) TE 36 (100) 90.4-100 Rahman et al. [42 ] (381) TE 325 (85.3) 81.4-88.5 Mandal et al. [43 ] (114) DOX 89 (78.1) 69.6-84.7 Macrolides Runa et al. [29 ] (5) E 5 (100) 56.6-100 Khatun et al. [30 ] (42) E 42 (100) 91.6-100 Al-Salauddin et al. [31 ] (50) E 42 (84) 71.5-91.7 AZM 6 (12) 5.6-23.8 Sarker et al. [32 ] (37) E 6 (16.2) 7.7-31.1 Islam et al. [34 ] (17) AZM 2 (11.8) 2.1-34.3 E 12 (70.6) 46.9-86.7 Saha et al. [36 ] (114) AZM 36 (31.6) 23.8-40.6 Al Azad et al. [37 ] (400) E 400 (100) 99.1-100 Tawyabur et al. [39 ] (55) E 55 (100) 93.5-100 Parvin et al. [40 ] (86) AZM 30 (34.9) 25.7-45.4 Ievy et al. [41 ] (36) E 35 (97.2) 85.8-99.9 Rahman et al. [42 ] (381) E 341 (89.5) 86.0-92.2 Polymyxins Runa et al. [29 ] (5) CL 5 (100) 56.6-100 Sarker et al. [32 ] (37) CL 8 (21.6) 11.4-37.2 Amin et al. [7 ] (104) CL 98 (94.2) 87.9-97.3 Saha et al. [36 ] (114) Pb 9 (7.9) 4.2-14.3 Al Azad et al. [37 ] (400) CL 106 (26.5) 22.4-31.0 Sobur et al. [38 ] (44) CL 13 (29.6) 18.2-44.2 Parvin et al. [40 ] (86) CL 9 (10.5) 5.6-18.7 Pb 7 (8.1) 3.9-15.9 Ievy et al. [41 ] (36) CL 4 (11.1) 4.4-25.3 Mandal et al. [43 ] (114) CL 17 (14.9) 9.5-22.6 Phenicols Sarker et al. [32 ] (37) C 10 (27) 15.4-42.9 Saha et al. [36 ] (114) C 59 (51.8) 42.7-60.7 Tawyabur et al. [39 ] (55) C 11 (20) 11.6-32.4 Parvin et al. [40 ] (86) C 27 (31.4) 22.6-41.8 Ievy et al. [41 ] (36) C 35 (97.2) 85.8-99.9 Rahman et al. [42 ] (381) C 190 (49.9) 44.9-54.9 Sulfonamides/folate pathway inhibition Parvez et al. [28 ] (11) STM 10 (90.9) 62.3-99.5 Sarker et al. [32 ] (37) STM 35 (94.6) 82.3-99.0 Amin et al. [7 ] (14) STM 12 (85.7) 60.1-97.5 Saha et al. [36 ] (114) SUL 51 (44.7) 35.9-53.9 Al Azad et al. [37 ] (400) STM 400 (100) 99.1-100 Parvin et al. [40 ] (86) STM 76 (88.4) 79.9-93.6 Rahman et al. [42 ] (381) STM 207 (54.3) 49.3-59.3 Cephamycins Amin et al. [7 ] (14) FOX 3 (21.4) 7.6-47.6 Saha et al. [36 ] (114) FOX 47 (41.2) 32.6-50.4 Parvin et al. [40 ] (86) FOX 42 (48.8) 38.6-59.2 Nitrofuran Parvez et al. [28 ] (11) NFT 3 (27.3) 9.8-56.6 Amin et al. [7 ] (14) NFT 3 (21.4) 7.6-47.6 Saha et al. [36 ] (114) NFT 72 (63.2) 54.0-71.5 Monobactams Parvin et al. [40 ] (86) AZN 1 (1.2) 0.1-6.3 Glycylcyclines Parvin et al. [40 ] (86) TIG 2 (2.3) 0.4-8.1
CI = confidence interval; AMX = amoxicillin; TE = tetracycline; STM = sulfamethoxazole-trimethoprim; NFT = nitrofurantoin; CIP = ciprofloxacin; LEV = levofloxacin; AMP = ampicillin; CL = colistin; E = erythromycin; NEO = neomycin; P = penicillin; GEN = gentamicin; CPX = cephalexin; NA = nalidixic acid; S = streptomycin; PLX = pefloxacin; OFX = ofloxacin; MOX = moxifloxacin; GAT = gatifloxacin; OXT = oxytetracycline; DOX = doxycycline; ERT = ertapenem; MEM = meropenem; IMP = imipenem; C = chloramphenicol; EN = enrofloxacin; NOR = norfloxacin; AZM = azithromycin; CTX = cefotaxime; CE = cephradine; CXM = cefuroxime; CEC = cefaclor; CRO = ceftriaxone; FOX = cefoxitin; CAZ = ceftazidime; CFM = cefixime; TAZ = tazobactam; SUL = sulfonamide; Pb = polymyxin B; FEP = cefepime; AMC = amoxiclav; AZN = aztreonam; TOB = tobramycin; AMK = amikacin; TIG = tigecycline.
